Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ASND

Ascendis Pharma A/S ADR

Mar 11 • 04:00PM ET

145.63

Dollar change +7.45
Percentage change 5.39	%

Healthcare • Biotechnology • Denmark • NASD

Peers: BIIB INCY NBIX REGN VRTX SRPT NKTR DNLI EXEL ADVM

| Held by: IBB TCAF MSSM SPDW FDG MEDI PFUT ONEQ HRTS TMAT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.13	Insider Own	0.74%	Shs Outstand	59.84M	Perf Week	-3.43%
Market Cap	8.71B	Forward P/E	123.70	EPS next Y	1.18	Insider Trans	0.00%	Shs Float	59.40M	Perf Month	20.48%
Income	-409.98M	PEG	-	EPS next Q	-1.54	Inst Own	107.02%	Short Float	6.11%	Perf Quarter	10.27%
Sales	391.88M	P/S	22.24	EPS this Y	44.64%	Inst Trans	2.61%	Short Ratio	7.82	Perf Half Y	22.22%
Book/sh	-1.83	P/B	-	EPS next Y	129.83%	ROA	-38.44%	Short Interest	3.63M	Perf Year	-0.44%
Cash/sh	9.68	P/C	15.04	EPS next 5Y	-	ROE	-867.62%	52W Range	111.09 - 158.00	Perf YTD	5.78%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-6.13%	ROI	-152.65%	52W High	-7.83%	Beta	0.59
Dividend TTM	-	Quick Ratio	0.84	Sales past 5Y	185.30%	Gross Margin	84.31%	52W Low	31.09%	ATR (14)	6.84
Dividend Ex-Date	-	Current Ratio	1.17	EPS Y/Y TTM	22.96%	Oper. Margin	-77.23%	RSI (14)	51.49	Volatility	5.61% 4.48%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	36.09%	Profit Margin	-104.62%	Recom	1.12	Target Price	210.67
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	58.45%	Payout	-	Rel Volume	0.86	Prev Close	138.18
Sales Surprise	46.46%	EPS Surprise	34.27%	Sales Q/Q	25.27%	Earnings	Feb 12 AMC	Avg Volume	464.24K	Price	145.63
SMA20	-1.44%	SMA50	5.80%	SMA200	8.63%	Trades		Volume	396,955	Change	5.39%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-25	Initiated	UBS	Buy	$196
Sep-05-24	Upgrade	Oppenheimer	Perform → Outperform	$180
Jun-25-24	Upgrade	TD Cowen	Hold → Buy	$156 → $175
May-31-24	Initiated	Stifel	Buy	$200
Dec-20-23	Initiated	Jefferies	Buy	$150
Jun-14-23	Resumed	Credit Suisse	Neutral	$89
Apr-05-23	Downgrade	Oppenheimer	Outperform → Perform
Apr-04-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$151 → $108
Apr-03-23	Downgrade	Credit Suisse	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy	$174
Aug-30-22	Resumed	Berenberg	Buy	$166
Mar-28-22	Resumed	Wedbush	Outperform	$163
Mar-15-22	Upgrade	BofA Securities	Neutral → Buy	$148 → $161
Mar-01-22	Initiated	Citigroup	Buy	$187
Feb-14-22	Upgrade	Oppenheimer	Perform → Outperform	$170
Jan-06-22	Initiated	Cowen	Market Perform	$136
Dec-08-21	Initiated	Wells Fargo	Overweight	$176
Oct-20-21	Downgrade	BofA Securities	Buy → Neutral	$164 → $169
Mar-30-21	Downgrade	Oppenheimer	Outperform → Perform
Mar-11-21	Resumed	Stifel	Buy	$190

Show Previous Ratings

Feb-24-25 04:01PM	Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-14-25 12:00AM	Ascendis Pharma AS (ASND) Q4 2024 Earnings Call Highlights: Strategic Growth and Market ... (GuruFocus.com)
Feb-13-25 02:40PM	Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? (Benzinga) +12.96%
Feb-12-25 04:05PM	Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs (GlobeNewswire) +5.55%
04:01PM	Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
04:01PM	Loading…
Feb-05-25 04:01PM	Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 (GlobeNewswire) +5.86%
Feb-04-25 07:23AM	Alibaba Cloud integrates DeepSeeks AI models (Verdict)
Jan-23-25 02:17AM	Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now? (Insider Monkey)
Jan-12-25 05:00PM	Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-25 08:30AM	Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-24 08:30AM	YORVIPATH (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults (GlobeNewswire)
Dec-18-24 06:28AM	Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk (TipRanks)
Dec-16-24 08:30AM	New InsiGHTS Trial of TransCon hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26 (GlobeNewswire) +5.18%
Dec-12-24 04:01PM	FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency (GlobeNewswire)
Dec-11-24 11:09AM	Er-Kim and Ascendis endocrine therapy agreement extended in Eurasia (Pharmaceutical Technology)
07:00AM	Loading…
Dec-10-24 07:00AM	Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets (GlobeNewswire)
Nov-14-24 04:01PM	Ascendis Pharma Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-07-24 04:01PM	Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 (GlobeNewswire)
Nov-05-24 12:12PM	Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA (Pharmaceutical Technology)
10:00AM	Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology (GuruFocus.com)
07:27AM	Ascendis Pharma and Novo Nordisk Join Forces (TipRanks)
07:10AM	Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform (TipRanks)
Nov-04-24 03:30PM	Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug (Quartz)
01:34PM	Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug (Benzinga)
07:00AM	Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases (GlobeNewswire)
Oct-01-24 10:13AM	Ascendis Pharma submits sBLA for growth hormone deficiency therapy (Pharmaceutical Technology)
Sep-30-24 08:30AM	New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide) Presented at ASBMR 2024 (GlobeNewswire)
08:30AM	Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency (GlobeNewswire)
Sep-25-24 03:50PM	BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish (Benzinga)
Sep-19-24 08:16PM	Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs (GlobeNewswire)
04:04PM	Loading…
Sep-18-24 04:04PM	Ascendis Pharma A/S Announces Proposed Public Offering of ADSs (GlobeNewswire)
Sep-17-24 09:02AM	Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last? (Zacks) +5.03%
01:30AM	RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares (GuruFocus.com)
Sep-16-24 04:01PM	Ascendis Rockets And Hammers BioMarin On New Results For Growth Drug (Investor's Business Daily) +17.07%
03:12PM	Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term (Benzinga)
07:00AM	Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo (GlobeNewswire)
Sep-14-24 07:54PM	Ascendis Pharma A/S (ASND): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-13-24 08:30AM	Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024 (GlobeNewswire)
Sep-11-24 05:37PM	Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults (GlobeNewswire)
Sep-04-24 05:02PM	Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In (Benzinga) -11.27%
04:48PM	Why Ascendis Pharma Stock Tumbled by 11% Today (Motley Fool)
04:02PM	Ascendis Pharma Undercuts 50-Day Line After Pricing Fiasco Prompts Guidance Cut (Investor's Business Daily)
09:14AM	Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout (Investor's Business Daily)
Sep-03-24 05:14PM	Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement (GlobeNewswire)
05:06PM	Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement (GlobeNewswire)
05:04PM	Ascendis Pharma Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Sep-02-24 09:01AM	Ascendis Pharma A/S (ASND) Q2 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-28-24 08:30AM	Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024 (GlobeNewswire)
Aug-14-24 12:31PM	Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath (Zacks)
08:59AM	Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains? (Zacks)
Aug-13-24 04:32AM	FDA approves Ascendis Pharmas YORVIPATH for hypoparathyroidism (Pharmaceutical Technology) +8.70%
Aug-12-24 04:55PM	Ascendis Pharma Zips Higher After FDA Approves Embattled Drug (Investor's Business Daily)
07:30AM	FDA approves Ascendis drug for rare endocrine condition (BioPharma Dive)
07:00AM	FDA Approves YORVIPATH (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults (GlobeNewswire)
Jul-07-24 09:01AM	2 Biotech Stocks With Big FDA Decisions Approaching Heres What Analysts Expect (TipRanks)
Jul-05-24 06:33AM	Pendopharm and Ascendis to distribute hypoparathyroidism treatment (Pharmaceutical Technology)
Jul-04-24 12:48PM	Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon PTH in Canada (PR Newswire)
Jun-24-24 04:45PM	Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024 (GlobeNewswire)
Jun-21-24 01:02AM	Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand (Insider Monkey) +5.12%
Jun-04-24 04:01PM	Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-24 04:01PM	Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024 (GlobeNewswire)
May-30-24 08:30AM	Ascendis to Spotlight Latest Updates for TransCon Rare Endocrinology Disease Portfolio at ENDO 2024 (GlobeNewswire)
May-15-24 01:57PM	FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months (Benzinga)
10:44AM	FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing (Zacks)
May-14-24 04:07PM	US Equity Markets Close Higher Tuesday as Producer Prices Rise (MT Newswires) -5.45%
03:20PM	Ascendis Pharma Says US FDA Extends Review Period on Hypoparathyroidism Treatment; Shares Drop (MT Newswires)
02:47PM	UPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapy (Reuters)
02:38PM	FDA extends review of Ascendis Pharma's hormone disorder therapy (Reuters)
02:31PM	Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism (GlobeNewswire)
May-13-24 09:29AM	Ascendis Says Late-Stage Trial Shows 'Significant' Improvements in Kidney Function for Adults Treated With TransCon PTH (MT Newswires)
08:30AM	Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial (GlobeNewswire)
May-09-24 08:30AM	Latest Clinical and Quality-of-Life Data for TransCon PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024 (GlobeNewswire)
May-06-24 09:59AM	Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 03:49AM	Ascendis Pharma Q1 Net Loss Widens, Revenue Rises (MT Newswires)
May-02-24 09:57PM	ASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024 (InvestorPlace)
04:01PM	Ascendis Pharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 04:46PM	Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024 (GlobeNewswire)
Apr-24-24 11:33AM	Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism (MT Newswires)
08:34AM	Why Earnings Season Could Be Great for Ascendis Pharma (ASND) (Zacks)
08:30AM	United Kingdom's MHRA Approves YORVIPATH (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism (GlobeNewswire)
Apr-02-24 06:13AM	Biotech With 520% Sales Growth Nears Next Buy Point (Investor's Business Daily)
Mar-22-24 12:09PM	Two Health Care Stocks Outperform S&P 500, Offer Entries (Investor's Business Daily)
05:27AM	Ascendis Pharma A/S (ASND) Rose on Positive Trial Results (Insider Monkey)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-07-24 08:14AM	Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4 (Insider Monkey)
Mar-04-24 08:30AM	Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-15-24 12:00PM	Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy? (Zacks)
09:40AM	Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year? (Zacks)
Feb-08-24 10:07AM	Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-07-24 04:01PM	Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
08:30AM	Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-06-24 08:46AM	Why Earnings Season Could Be Great for Ascendis Pharma (ASND) (Zacks)
Jan-31-24 04:15PM	Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024 (GlobeNewswire) +9.00%
04:01PM	Ascendis Pharma Launches 2nd TransCon Product: YORVIPATH Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism (GlobeNewswire)
Jan-29-24 08:30AM	New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors (GlobeNewswire)
Jan-08-24 06:01PM	Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe and Turkey (GlobeNewswire) +6.57%
08:20AM	Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries (GlobeNewswire)
Jan-07-24 05:45PM	Ascendis Pharma Introduces Vision 2030 (GlobeNewswire)
02:00PM	Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries (PR Newswire)
Dec-28-23 04:15PM	Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
JENSEN MICHAEL WOLFF	Officer	Mar 07 '25	Proposed Sale	146.46	4,000	585,846	Mar 07 05:03 PM
JENSEN FLEMMING STEEN	Officer	Mar 06 '25	Proposed Sale	152.39	10,000	1,523,933	Mar 06 04:35 PM
JENSEN MICHAEL WOLFF	Officer	Mar 06 '25	Proposed Sale	152.25	1,614	245,735	Mar 06 04:35 PM
MIKKELSEN JAN MOLLER	Officer	Mar 05 '25	Proposed Sale	155.13	7,789	1,208,292	Mar 05 04:51 PM
Bodenhoff Mads	Officer	Mar 05 '25	Proposed Sale	155.01	2,254	349,403	Mar 05 02:31 PM
Hartvig Camilla Harder	Officer	Mar 04 '25	Proposed Sale	152.12	2,222	338,021	Mar 04 08:38 PM
Bodenhoff Mads	Officer	Mar 04 '25	Proposed Sale	152.12	2,828	430,208	Mar 04 08:32 PM
Fairey William	Director	Mar 04 '25	Proposed Sale	152.12	1,006	153,037	Mar 04 08:27 PM
IMANI SIHAM	Director	Mar 04 '25	Proposed Sale	152.12	1,006	153,037	Mar 04 08:22 PM
Morrison Lisa	Director	Mar 04 '25	Proposed Sale	152.12	1,470	223,623	Mar 04 08:15 PM
HOLTUG LARS	Director	Mar 04 '25	Proposed Sale	152.12	1,470	223,623	Mar 04 08:12 PM
Cha Albert	Director	Mar 04 '25	Proposed Sale	152.12	1,470	223,623	Mar 04 08:09 PM
SINGEL STINA	Officer	Mar 04 '25	Proposed Sale	152.12	13,344	2,029,949	Mar 04 08:04 PM
SMITH SCOTT THOMAS	Officer	Mar 04 '25	Proposed Sale	152.12	13,344	2,029,949	Mar 04 08:00 PM
JENSEN MICHAEL WOLFF	Officer	Mar 04 '25	Proposed Sale	152.12	13,344	2,029,949	Mar 04 07:55 PM
PEDERSEN ANNI LOTTE KIRSTINE S	Officer	Mar 04 '25	Proposed Sale	152.12	7,719	1,174,249	Mar 04 07:50 PM
SPROGOE KENNETT	Officer	Mar 04 '25	Proposed Sale	152.12	7,719	1,174,249	Mar 04 07:45 PM
JENSEN FLEMMING STEEN	Officer	Mar 04 '25	Proposed Sale	152.12	7,719	1,174,249	Mar 04 07:40 PM
MIKKELSEN JAN MOLLER	Officer	Mar 03 '25	Proposed Sale	155.14	7,800	1,210,089	Mar 03 04:58 PM
SINGEL STINA	Officer	Feb 20 '25	Proposed Sale	155.20	2,729	423,542	Feb 21 06:11 AM
SMITH SCOTT THOMAS	Officer	Feb 20 '25	Proposed Sale	154.27	10,000	1,542,671	Feb 20 04:15 PM
PEDERSEN ANNI LOTTE KIRSTINE S	Officer	Feb 19 '25	Proposed Sale	152.70	39,375	6,012,750	Feb 19 05:06 PM
JENSEN MICHAEL WOLFF	Officer	Feb 19 '25	Proposed Sale	151.32	5,000	756,607	Feb 19 04:56 PM
JENSEN FLEMMING STEEN	Officer	Feb 18 '25	Proposed Sale	146.80	10,000	1,467,977	Feb 18 05:30 PM
SINGEL STINA	Officer	Dec 10 '24	Proposed Sale	129.13	2,119	273,621	Dec 10 05:16 PM
JENSEN MICHAEL WOLFF	Officer	Dec 10 '24	Proposed Sale	129.13	2,119	273,621	Dec 10 05:07 PM
PEDERSEN ANNI LOTTE KIRSTINE S	Officer	Dec 10 '24	Proposed Sale	129.13	1,222	157,794	Dec 10 05:02 PM
SPROGOE KENNETT	Officer	Dec 10 '24	Proposed Sale	129.13	1,222	157,794	Dec 10 04:59 PM
SMITH SCOTT THOMAS	Officer	Dec 10 '24	Proposed Sale	129.13	2,119	273,621	Dec 10 04:58 PM
JENSEN FLEMMING STEEN	Officer	Dec 10 '24	Proposed Sale	129.13	1,222	157,794	Dec 10 04:55 PM
MIKKELSEN JAN MOLLER	Officer	Dec 10 '24	Proposed Sale	129.13	5,292	683,342	Dec 10 04:44 PM
JENSEN FLEMMING STEEN	Officer	Dec 03 '24	Proposed Sale	131.37	9,375	1,231,574	Dec 03 04:35 PM
Hartvig Camilla Harder	Officer	Nov 19 '24	Proposed Sale	122.38	19,468	2,382,402	Nov 19 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ASND

Ascendis Pharma A/S ADR

Upgrade your FINVIZ experience